The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treatment of pancreatic adenocarcinoma
Publication date: November 2026 Source: Biomedicine & Pharmacotherapy, Volume 204 Author(s): Davide Busato, Monica Argenziano, Maurizio Polano, Sara Capolla, Monica Mossenta, Carmela Tangredi, Federico Riccardi, Alessandro Mangogna, Paolo Durigutto, Giorgia Fontana, Luigina De Leo, Daniele Sblattero, Paolo Macor, Giuseppe Toffoli, Roberta Cavalli, Michele Dal Bo
The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treatment of pancreatic adenocarcinoma. // Biomedicine & Pharmacotherapy. – URL: https://www.sciencedirect.com/science/article/pii/S0753332226009923?dgcid=rss_sd_all
The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treatment of pancreatic adenocarcinoma. Biomedicine & Pharmacotherapy. https://www.sciencedirect.com/science/article/pii/S0753332226009923?dgcid=rss_sd_all
“The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treatment of pancreatic adenocarcinoma.” Biomedicine & Pharmacotherapy.
@article{article106832,
title = {The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treatment of pancreatic adenocarcinoma},
journal = {Biomedicine \& Pharmacotherapy},
url = {https://www.sciencedirect.com/science/article/pii/S0753332226009923?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...